Evidence map›Paper›PMID 33089306›Full record

ArticleThe Journal of antimicrobial chemotherapy2021

Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial-authors' response.

Minh Patrick Lê, Nathan Peiffer-Smadja, Jeremie Guedj, Nadège Neant, France Mentré, Florence Ader, Yazdan Yazdanpanah, Gilles Peytavin, C-20-15 DisCoVeRy French Steering Committee

Registry-linked trialAbstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of antimicrobial chemotherapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04315948 (Multi-centre, Adaptive, Randomized Trial of the Safety and Efficacy of Treatments of COVID-19 in Hospitalized Adults), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04315948 phase3completednot on this map

Multi-centre, Adaptive, Randomized Trial of the Safety and Efficacy of Treatments of COVID-19 in Hospitalized Adults

TypeinterventionalSponsorInstitut National de la Santé Et de la Recherche Médicale, FranceRan2020 to 2023Enrolled1,552ConditionsCorona Virus InfectionArmsRemdesivir, Lopinavir/ritonavir, Interferon Beta-1A, Hydroxychloroquine, Standard of care
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Minh Patrick LêAP-HP, Bichat Claude Bernard Hospital, Pharmacology-Toxicology Department, 75018 Paris, France.
Nathan Peiffer-SmadjaAP-HP, Bichat Claude Bernard Hospital, Tropical and infectious diseases Department, 75018 Paris, France.
Jeremie GuedjIAME, INSERM, UMRS1137, Université de Paris, 75018 Paris, France.
Nadège NeantIAME, INSERM, UMRS1137, Université de Paris, 75018 Paris, France.
France MentréIAME, INSERM, UMRS1137, Université de Paris, 75018 Paris, France.
Florence AderHospices Civils de Lyon, Department of Infectious Diseases, Croix-Rousse Hospital, 104 Grande-Rue de la Croix-Rousse, Lyon 69004, France.
Yazdan YazdanpanahAP-HP, Bichat Claude Bernard Hospital, Tropical and infectious diseases Department, 75018 Paris, France.
Gilles PeytavinAP-HP, Bichat Claude Bernard Hospital, Pharmacology-Toxicology Department, 75018 Paris, France.
C-20-15 DisCoVeRy French Steering Committee

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Coronavirus InfectionsCOVID-19Pneumonia, ViralHumansHydroxychloroquinePandemicsSARS-CoV-2Hydroxychloroquine

Identifiers

PMID33089306
PMCPMC7665555

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.